2017/18 and 2018/19 seasonal influenza vaccine safety surveillance, Canadian National Vaccine Safety (CANVAS) Network
2017/18 and 2018/19 seasonal influenza vaccine safety surveillance, Canadian National Vaccine Safety (CANVAS) Network
复制标题
DOI：
10.2807/1560-7917.es.2020.25.22.1900470
复制
发表时间：
2020-06-04
期刊：
影响因子：
19
通讯作者：
Mccarthy, Anne E.
中科院分区：
文献类型：
--
作者：
Bettinger, Julie A.;De Serres, Gaston;Mccarthy, Anne E.
背景：加拿大国家疫苗安全（CANVAS）网络监测加拿大季节性流感疫苗的安全性。目的加强对季节性流感和大流行性流感疫苗的监测。研究方法：在2017/18和2018/19流感季节，成年人（≥ 15岁）和接种季节性流感疫苗的儿童的父母参加了一项基于网络的主动监测观察性研究。参与者完成了一项关于接种疫苗后前7天内发生的健康事件的在线调查。在上一个季节接种流感疫苗但尚未接种本季节疫苗的参与者是未接种疫苗的对照组。结果：在2017/18年度，43，751名参与者和2018/19年度，47，798名参与者完成了在线安全性调查。在2017/18年度，30，173名参与者中有957人接种了疫苗（3.2%; 95%置信区间（CI）：3.03.4），2018/19年度25,799名参与者中有857人接种疫苗（3.3%; 95% CI：3.13.5）报告了严重程度足以妨碍其正常日常活动和/或导致其就医的健康问题（包括住院治疗）。相比之下，在每个季节，13，578例对照中有323例（2.4%; 95%CI：2.12.6），21，999例对照中有544例（2.5%; 95%CI：2.32.7）。接种疫苗的成人和儿童的事件发生率高于背景发生率，并且与特定的流感疫苗相关。较高的事件发生率与全身症状和偏头痛/头痛相关。结论：在2017/18和2018/19年度，季节性流感疫苗接种后报告的事件发生率高于疫苗接种前。该信号与几种季节性流感疫苗产品有关。
Background: The Canadian National Vaccine Safety (CANVAS) network monitors the safety of seasonal influenza vaccines in Canada. Aim To provide enhanced surveillance for seasonal influenza and pandemic influenza vaccines. Methods: In 2017/18 and 2018/19 influenza seasons, adults (>= 15 years of age) and parents of children vaccinated with the seasonal influenza vaccine participated in an observational study using web-based active surveillance. Participants completed an online survey for health events occurring in the first 7 days after vaccination. Participants who received the influenza vaccine in the previous season, but had not yet been vaccinated for the current season, were unvaccinated controls. Results: In 2017/18, 43,751 participants and in 2018/19, 47,798 completed the online safety survey. In total, 957 of 30,173 participants vaccinated in 2017/18 (3.2%; 95% confidence interval (CI): 3.03.4) and 857 of 25,799 participants vaccinated in 2018/19 (3.3%; 95% CI: 3.13.5) reported a health problem of sufficient intensity to prevent their normal daily activities and/or cause them to seek medical care (including hospitalisation). This compared to 323 of 13,578 (2.4%; 95% CI: 2.12.6) and 544 of 21,999 (2.5%; 95% CI: 2.32.7) controls in each respective season. The event rate in vaccinated adults and children was higher than the background rate and was associated with specific influenza vaccines. The higher rate of events was associated with systemic symptoms and migraines/headaches. Conclusion: In 2017/18 and 2018/19, higher rates of events were reported following seasonal influenza vaccination than in the pre-vaccination period. This signal was associated with several seasonal influenza vaccine products.